Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials

Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation

(2013) Lars Wallentin et al.   CIRCULATION

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

(2013) Amanda R. Harrington et al.   STROKE

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

(2012) Steve Deitelzweig et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention

(2011) Stephanie R. Earnshaw et al.   ARCHIVES OF INTERNAL MEDICINE

A New Risk Scheme to Predict Warfarin-Associated Hemorrhage

(2011) Margaret C. Fang et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

(2011) Valentin Fuster et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective

(2011) Anuraag Kansal et al.   THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation

(2010) Catherine J. Mercaldi et al.   STROKE

Cost of atrial fibrillation in United States managed care organizations

(2009) Michael H. Kim et al.   ADVANCES IN THERAPY

Increasing Prevalence of Atrial Fibrillation and Flutter in the United States

(2009) Gerald V. Naccarelli et al.   AMERICAN JOURNAL OF CARDIOLOGY

Relationship between aging and dosage of warfarin: The current status of warfarin anticoagulant therapy for Japanese outpatients in a department of cardiovascular medicine

(2009) Takeshi Miura et al.   Journal of Cardiology

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antithrombotic Therapy in Atrial Fibrillation

(2008) Daniel E. Singer et al.   CHEST

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION